Report forecast the Human Growth Hormone market in
the US to grow at a CAGR of 3.86 percent over the period 2014-2019.
Human growth hormone, also known as somatotropin, is
a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the
anterior pituitary, and it is required to attain normal size for children and
adolescents. It also has major effects on lipid and carbohydrate metabolism of
an individual. The effects of human growth hormone are mainly mediated by IGF-1
and IGF-2. There are two forms of recombinant human growth hormone approved in
the market: Somatropin and Somatrem. Somatropin has 191 amino acids and
Somatrem contains 192 amino acids. Growth hormone deficiency can occur either
due to a damage to the pituitary or the hypothalamus gland, or can also be
acquired genetically. Some of the signs of growth hormone deficiency are
adiposity, short stature, and hypoglycemia.
This report covers the present scenario and the
growth prospects of the Human Growth Hormone market in the US for the period
2015-2019. To calculate the market size, the report considers revenue generated
from the sales of the various human growth hormone drugs available in the US
for the treatment of growth hormone deficiency.
According to the report, human growth hormone is
administered to patients with various complications such as growth hormone
deficiency, Noonan and Turner syndromes, and infants who are born small for
their gestational age. High incidence and prevalence of these diseases result
in increased demand for human growth hormone
Further, the report states that all of the approved
drugs available in the market are biologics. The development process of these
biologics is expensive, thereby leading to increased pricing of these drugs.
These biologics need to be kept in cold storage to retain their efficacy and
avoid local reactions. Therefore, special machinery and care are required to
ensure the supply of potent growth hormones.
The Human Growth Hormone Market in the US 2015-2019,
has been prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the landscape of the Human Growth Hormone
market in the US and its growth prospects in the coming years. The report
includes a discussion of the key vendors operating in this market.
key players in the Human Growth Hormone Market in the
US: F. Hoffmann-La Roche Ltd., Merck Serono SA, Novo Nordisk A/S and Pfizer
Inc.
Other Prominent Vendors in the market are: Eli Lilly,
Ipsen, Novartis and Teva Pharmaceutical.
Market Driver
- Demand for Human Growth Hormone
- For a full, detailed list, view our report
Market
Challenge
- High Cost of Therapy
- For a full, detailed list, view our report
Market Trend
- Growing Focus on Needle-free Drug Delivery Devices
- For a full, detailed list, view our report
Key Questions
Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 84 pages “Human Growth Hormone Market in the US 2015-2019” report
covers the Executive Summary, List of Abbreviations, Scope of the Report,
Market Research Methodology, Introduction, Market Landscape, Human Growth
Hormone: An Overview, Market Landscape, Buying Criteria, Market Growth Drivers,
Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges,
Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis.
For further information on this report, please visit- http://mrr.cm/4fK
Browse more Healthcare
reports at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.